VERAXA Biotech pushes ahead with BiTAC cancer platform after NASDAQ listing
VERAXA Biotech has joined the NASDAQ and is moving fast on its oncology pipeline built around the BiTAC platform. The Swiss company is entering a new phase.
Veraxa Biotech 1 article
Veraxa Biotech is an antibody-engineering company developing bispecific biologics and site-specific antibody-drug conjugates built around antibody engineering. The biologic strategy also includes bispecific antibody-drug conjugates and bispecific T-cell engagers, which clarify the binding format, pathway or disease biology involved. A complementary scientific marker is hydrophilic tetrazine payload chemistry, which helps resolve the company identity of Veraxa Biotech.